Table 1.
Clinical and Demographic Characteristics of Patients
| Total 2002–2011 [number (%)] | 2002–2006 [number (%)] | 2007–2011 [number (%)] | p value | |
|---|---|---|---|---|
| Sex | ||||
| Female | 29 (16) | 20 (21) | 9 (10) | |
| Male | 152 (84) | 75 (79) | 77 (90) | |
| Total | 181 (100) | 95 (100) | 86 (100) | |
| Age | ||||
| Mean (range) | 31.4 (18–73) | 29.6 (18–67) | 33.2 (19–73) | |
| Transmission route | ||||
| MSM | 96 (53) | 35 (37) | 61 (71) | p<0.0001 |
| Heterosexual | 55 (30) | 38 (40) | 17 (20) | p=0.0123 |
| IVDU | 9 (5) | 8 (8) | 1 (1) | p=0.0365 |
| Blood product | 3 (2) | 3 (3) | 0 | |
| Unknown | 18 (10) | 11 (12) | 7 (8) | |
| Total | 181 (100) | 95 (100) | 86 (100) | |
| CDC stage | ||||
| CDC stage A | 75 (41) | 29 (30) | 46 (53) | p=0.0022 |
| CDC stage B | 30 (17) | 18 (19) | 12 (14) | |
| CDC stage C | 61 (34) | 36 (38) | 25 (29) | |
| Unknown | 15 (8) | 12 (13) | 3 (4) | |
| Total | 181 (100) | 95 (100) | 86 (100) | |
| CD4 cells/mm3 | ||||
| Mean (range) | 261 (1–1,320) | 180 (1–773) | 325 (4–1,320) | p=0.0004 |
| STI | ||||
| Positive | 45 (25) | 14 (15) | 31 (36) | p<0.001 |
| Negative | 118 (65) | 68 (72) | 50 (59) | |
| Unknown | 18 (10) | 13 (13) | 5 (5) | |
| Total | 181 (100) | 95 (100) | 86 (100) | |
| HBV infection | ||||
| 17 (9.4) | 5 (5.3) | 12 (13.9) | ||
| HCV infection | ||||
| 12 (6.6) | 9 (9.5) | 3 (3.5) | ||
MSM, men who have sex with men; IDU, intravenous drug user; hepatitis B virus (HBV) coinfection was determined by the presence of HBsAg; hepatitis C virus (HCV) coinfection was determined by the presence of anti-HCV antibodies; STI, history of sexually transmitted infections, including positivity to anti-HBcAg.